Matthias Eberl
Cardiff University
Cardiff
CF10 3XQ
United Kingdom
Scientific summary
Aminobisphosphonates such as zoledronate (Zometa) and ibandronate (Bonviva) are current standard of care for metastatic bone disease in breast and prostate cancer. The ABCSG-12 trial has shown that adjuvant zol added to standard anti-hormonal therapy reduces the risk of recurrence in …
Recent publications
In vivo manipulation of V gamma 9V delta 2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients
Clin Exp Immunol.2010;161 :290-297
Monocytes and gamma delta T cells: close encounters in microbial infection
Trends Immunol.2009;30 :562-568
Increase text
Decrease text
Print this page